Silvia Moretti

Silvia Moretti

Auto-generated profile, based on publicly available information

Silvia Moretti

Department of Dermatology, University of Florence, Florence, Italy

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2002 in Pigment Cell Research
Verified
Journal Article
Closed access
PDF file
SMSilvia Moretti
Silvia Moretti
ASAdelina Spallanzani
Adelina Spallanzani
LALauretta Amato
Lauretta Amato
GHGiuseppe Hautmann
Giuseppe Hautmann
IGIsabella Gallerani
Isabella Gallerani
PFPaolo Fabbri
Paolo Fabbri

1 March 2013 in Laboratory Investigation
Verified
Journal Article
Closed access
SMSilvia Moretti
Silvia Moretti
DMDaniela Massi
Daniela Massi
VFValentina Farini
Valentina Farini
GBGianna Baroni
Gianna Baroni
MPMatteo Parri
Matteo Parri
PCPaola Chiarugi
Paola Chiarugi

9 March 2015 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
RCRoberta Colucci
Roberta Colucci
FDFederica Dragoni
Federica Dragoni
SMSilvia Moretti
Silvia Moretti
Vitiligo is an acquired dermatological disease frequently associated with autoimmune thyroid disorders. Several theories have been proposed so far to unravel the complex vitiligo pathogenesis. Currently, the autocytotoxic and the autoimmune theories are the most accredited hypothesis, since they are sustained by several important clinical and experimental evidences. A growing body of evidences shows that autoimmunity and oxidative stress strictly interact to finally determine melanocyte loss. In this scenario, associated thyroid autoimmunity might play an active and important role in triggering and maintaining the depigmentation process of vitiligo.

6 July 2021 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
FVFrancesco Vitali
Francesco Vitali
RCR. Colucci
R. Colucci
MPMonica Di Paola
Monica Di Paola
MPM. Pindo
M. Pindo
Carlotta De FilippoCarlotta De Filippo
Carlotta De Filippo
DCDuccio Cavalieri
Duccio Cavalieri
Background The microbiome is emerging as a crucial player of the immune checkpoint in cancer. Melanoma is a highly immunogenic tumour, and the gut microbiome composition has been correlated to prognosis and evolution of advanced melanoma and proposed as biomarker for immune checkpoint therapy. Objectives We investigated the gut fungal and bacterial composition in early-stage melanoma and correlated microbial profiles with histopathological features. Methods Bacterial 16S rRNA and fungal ITS region sequencing was performed from faecal samples of patients affected by stage I and II melanoma, and healthy controls. A meta-analysis with gut microbiota data from metastatic melanoma patients was also carried out. Results We found a combination of gut fungal and bacterial profiles significantly discriminating M patients from controls. In melanoma patients, we observed an abundance of Prevotella copri and yeasts belonging to the Saccharomycetales order. We found bacterial and fungal community correlated to melanoma invasiveness, whereas specific fungal profile correlated to melanoma regression. Bacteroides was identified as general marker of immunogenicity, being shared by regressive and invasive melanoma. In addition, the bacterial community from stage I and II patients were different in structure and richer than those from metastatic melanoma patients. Conclusions Gut microbiota composition in early-stage melanoma changes along the gradient from in situ to invasive (and metastatic) melanoma. Changes in the microbiota and mycobiota are correlated to the histological features of early-stage melanoma, and to the clinical course and response to immune therapies of advanced stage melanoma, through a direct or indirect immunomodulation

29 December 2011 in Pathology Research International
Verified
Journal Article
Open access
PDF file
MGMassimiliano Galeone
Massimiliano Galeone
RCRoberta Colucci
Roberta Colucci
ADAngelo Massimiliano D'Erme
Angelo Massimiliano D'Erme
SMSilvia Moretti
Silvia Moretti
TLTorello Lotti
Torello Lotti
Behçet's disease is a multisystem inflammatory disorder characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesions. The cause of Behçet's disease remains unknown, but epidemiologic findings suggest that an autoimmune process is triggered by an environmental agent in a genetically predisposed individual. An infectious agent could operate through molecular mimicry, and subsequently the disease could be perpetuated by an abnormal immune response to an autoantigen in the absence of ongoing infection. Potentia bacterial are Saccharomyces cerevisiae, mycobacteria, Borrelia burgdorferi, Helicobacter pylori, Escherichia coli, Staphylococcus aureus, and Mycoplasma fermentans, but the most commonly investigated microorganism is Streptococcus sanguinis. The relationship between streptococcal infections and Behçet's disease is suggested by clinical observations that an unhygienic oral condition is frequently noted in the oral cavity of Behçet's disease patients. Several viral agents, including herpes simplex virus-1, hepatitis C virus, parvovirus B19, cytomegalovirus, Epstein-Barr virus and varicella zoster virus, may also have some role.

1 March 2008 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
TLTorello Lotti
Torello Lotti
AGAlessia Gori
Alessia Gori
FZFabio Zanieri
Fabio Zanieri
RCRoberta Colucci
Roberta Colucci
SMSilvia Moretti
Silvia Moretti
Vitiligo is a cosmetically disfiguring condition, and, although there is no therapeutic full solution yet, some treatment may induce good results in most patients. The disease can be successfully treated with various medical options. Both nonfocused or focused narrowband ultraviolet B phototherapy represents the current treatment of choice, to minimize side effects and reach optimal clinical results. Topical novel approaches are also considered. Surgical methods, consisting of autologous transplantation methods, is generally recommended for focal/stable vitiligo, after medical therapy has failed. Finally, for patients with extensive vitiligo, depigmentation of the residual melanin should be taken into account.